KZR - Kezar Life Sciences Inc

KZR - Kezar Life Sciences Inc

https://www.kezarlifesciences.com

Recent News

Powered by Alpha Vantage

FDA Lifts Pause On Kezar's Liver Drug Trial-Next Stop Lupus Study - Kezar Life Sciences ( NASDAQ:KZR )

Benzinga • 1 month, 4 weeks ago • score: 0.17

FDA lifts partial clinical hold on Kezar's Phase 2a AIH study for zetomipzomib. Kezar plans to seek hold removal for lupus nephritis after a safety review. Get daily-updated rankings across momentum, growth, value, trends, and quality to spot the strongest stocks in any market.

Kezar Life Sciences ( KZR ) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Commentary • 3 months, 2 weeks ago • score: 0.31

Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study - Kezar Life Sciences ( NASDAQ:KZR )

Benzinga • 10 months, 4 weeks ago • score: 0.28

On Thursday, Kezar Life Sciences, Inc KZR decided to terminate the PALIZADE Phase 2b trial in patients with active lupus nephritis ( LN ) and focus clinical development efforts on zetomipzomib in autoimmune hepatitis ( AIH ) .

What Makes Kezar Life Sciences ( KZR ) a New Buy Stock

Zacks Commentary • 10 months, 4 weeks ago • score: 0.35

Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, is dedicated to the discovery and development of new small molecule therapies to address the unmet needs in immune-mediated diseases and cancer in the United States. The company is headquartered in South San Francisco, California.

52W High

$9.18

52W Low

$3.62

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.61

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.06

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

6.03

P/B (<3 favorable)

0.33

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

10.57%

Institutions (25–75% balanced)

61.12%

Shares Outstanding

7,323,100

Float

4,691,500

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

-54,035,000

EPS (TTM)

-9.70

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.58%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—